Title:New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Volume: 17
Issue: 3
Author(s): Anton P. Bonartsev, Anton L. Zernov, Sergey G. Yakovlev, Irina I. Zharkova, Vera L. Myshkina, Tatiana K. Mahina, Garina A. Bonartseva, Natalia V. Andronova, Galina B. Smirnova, Juliya A. Borisova, Mikhail S. Kalishjan, Konstantin V. Shaitan and Helena M. Treshalina
Affiliation:
Keywords:
Paclitaxel, poly(3-hydroxybutyrate), microparticles, spray-drying, sustained release, antitumor activity, adaptive therapy.
Abstract: Background: Poly(hydroxyalkanoates) (PHA) have recently attracted increasing attention due to their
biodegradability and high biocompatibility, which makes them suitable for the development of new prolong drug
formulations.
Objective: This study was conducted to develop new prolong paclitaxel (PTX) formulation based on poly(3-
hydroxybutyrate) (PHB) microparticles.
Method: PHB microparticles loaded with antitumor cytostatic drug PTX were obtained by spray-drying method using
Nano Spray Dryer B-90. The PTX release kinetics in vitro from PHB microparticles and their cytotoxity on murine
hepatoma cell line MH-22a were studied. Microparticles antitumor activity in vivo was studied using intraperitoneally
(i.p.) transplanted tumor models: murine Lewis lung carcinoma and xenografts of human breast cancer RMG1.
Results: Uniform PTX release from PHB-microparticles during 2 months was observed. PTX-loaded PHB microparticles
have demonstrated a significant antitumor activity versus pure drug both in vitro in murine hepatoma cells and in vivo
when administered i.p. to mice with murine Lewis lung carcinoma and xenografts of human breast cancer RMG1.
Conclusion: The developed technique of PTX sustained delivery from PHB-microparticles has therapeutic potential as
prolong anticancer drug formulation.
